{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T17:12:19Z","timestamp":1775668339069,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T00:00:00Z","timestamp":1681776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Some patients with connective tissue disease (CTD)-associated interstitial lung disease (ILD) progress to pulmonary fibrosis over their disease course despite initial improvement, potentially indicating a poor prognosis. Transbronchial lung cryobiopsy (TBLC) is a new bioptic approach used in diffuse parenchymal lung diseases. This study of CTD-ILD assessed the utility of TBLC in determining therapeutic decision-making strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed medical records of 31 consecutive CTD-ILD patients who underwent TBLC focusing on radio-pathological correlation and disease course. A TBLC-based usual interstitial pneumonia (UIP) score was used that assessed three morphologic descriptors: i) patchy fibrosis, ii) fibroblastic foci, and iii) honeycombing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among the patients with CTD-ILD, 3 had rheumatoid arthritis, 2 systemic sclerosis, 5 polymyositis\/dermatomyositis, 8 anti-synthetase syndrome, 6 Sj\u00f6gren\u2019s syndrome, and 5 had microscopic polyangiitis. Pulmonary function test results showed a mean %FVC of 82.4% and %DL\n                      <jats:sub>CO<\/jats:sub>\n                      of 67.7%. Among the 10 CTD patients and TBLC-proven pathological UIP, 3 patients had prominent inflammatory cells in addition to a framework of UIP, and pulmonary function of most patients improved with anti-inflammatory agents. Six (40%) of 15 patients with TBLC-based UIP score\u2009\u2265\u20091 had a progressive disease course during follow-up, of whom 4 patients received anti-fibrotic agents.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>TBLC in patients with CTD-ILD can help determine an appropriate medication strategy, particularly when UIP-like lesions are present. TBLC may be useful when judging which agents to prioritize, anti-inflammatory or anti-fibrotic, is difficult. Moreover, additional information from TBLC may be beneficial when considering early intervention with anti-fibrotic agents in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-023-02429-0","type":"journal-article","created":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T06:04:04Z","timestamp":1681797844000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Can transbronchial lung cryobiopsy benefit adaptive treatment strategies in connective tissue disease-associated interstitial lung disease?"],"prefix":"10.1186","volume":"23","author":[{"given":"Hideaki","family":"Yamakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiko","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Takatsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomotaka","family":"Nishizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Kawabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanobu","family":"Horikoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidekazu","family":"Matsushima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,18]]},"reference":[{"key":"2429_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3097","volume":"12","author":"FV Castelino","year":"2010","unstructured":"Castelino FV, Varga J. Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management. Arthritis Res Ther. 2010;12:213.","journal-title":"Arthritis Res Ther"},{"key":"2429_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/MCP.0b013e3283483ea5","volume":"17","author":"ST Panopoulos","year":"2011","unstructured":"Panopoulos ST, Sfikakis PP. Biological treatments and connective tissue disease associated interstitial lung disease. Curr Opin Pulm Med. 2011;17:362\u20137.","journal-title":"Curr Opin Pulm Med"},{"key":"2429_CR3","doi-asserted-by":"publisher","first-page":"100419","DOI":"10.1016\/j.ejro.2022.100419","volume":"9","author":"H Yoo","year":"2022","unstructured":"Yoo H, Hino T, Hwang J, Franks TJ, Han J, Im Y, et al. Connective tissue disease-related interstitial lung disease (CTD-ILD) and interstitial lung abnormality (ILA): evolving concept of CT findings, pathology and management. Eur J Radiol Open. 2022;9:100419.","journal-title":"Eur J Radiol Open"},{"key":"2429_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1111\/resp.13977","volume":"26","author":"AS Jee","year":"2021","unstructured":"Jee AS, Sheehy R, Hopkins P, Corte TJ, Grainge C, Troy LK, et al. Diagnosis and management of connective tissue disease-associated interstitial lung disease in Australia and New Zealand: a position statement from the thoracic society of Australia and New Zealand. Respirology. 2021;26:23\u201351.","journal-title":"Respirology"},{"key":"2429_CR5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.resinv.2021.04.011","volume":"59","author":"Y Kondoh","year":"2021","unstructured":"Kondoh Y, Makino S, Ogura T, Suda T, Tomioka H, Amano H, et al. 2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respir Investig. 2021;59:709\u201340.","journal-title":"Respir Investig"},{"key":"2429_CR6","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, Mayes MD, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380:2518\u201328.","journal-title":"N Engl J Med"},{"key":"2429_CR7","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718\u201327.","journal-title":"N Engl J Med"},{"key":"2429_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000456671","volume":"93","author":"C Ravaglia","year":"2017","unstructured":"Ravaglia C, Wells AU, Tomassetti S, Dubini A, Cavazza A, Piciucchi S, et al. Transbronchial lung cryobiopsy in diffuse parenchymal lung disease: comparison between biopsy from 1 segment and biopsy from 2 segments - diagnostic yield and complications. Respiration. 2017;93:285\u201392.","journal-title":"Respiration"},{"key":"2429_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1159\/000484055","volume":"95","author":"J Hetzel","year":"2018","unstructured":"Hetzel J, Maldonado F, Ravaglia C, Wells AU, Colby TV, Tomassetti S, et al. Transbronchial Cryobiopsies for the diagnosis of diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a call for standardization of the Procedure. Respiration. 2018;95:188\u2013200.","journal-title":"Respiration"},{"key":"2429_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","volume":"8","author":"LK Troy","year":"2020","unstructured":"Troy LK, Grainge C, Corte TJ, Williamson JP, Vallely MP, Cooper WA, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8:171\u201381.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2429_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The american Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315\u201324.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2429_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1056\/NEJM197502132920706","volume":"292","author":"A Bohan","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344\u20137.","journal-title":"N Engl J Med"},{"issue":"11","key":"2429_CR13","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1002\/art.38098","volume":"65","author":"F n den Hoogen","year":"2013","unstructured":"n den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Arthritis Rheum. 2013;65(11):2737\u201347.","journal-title":"Arthritis Rheum"},{"issue":"21","key":"2429_CR14","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1056\/NEJM197611182952101","volume":"295","author":"GC Sharp","year":"1976","unstructured":"Sharp GC, Irvin WS, May CM, Holman HR, McDuffie FC, Hess EV, et al. Association of antibodies to ribonucleoprotein and sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295(21):1149\u201354.","journal-title":"N Engl J Med"},{"issue":"6","key":"2429_CR15","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, et al. Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the european criteria proposed by the american-european Consensus Group. Ann Rheum Dis. 2002;61(6):554\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2429_CR16","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1253\/circj.CJ-19-0773","volume":"84","author":"M Isobe","year":"2020","unstructured":"Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, et al. JCS Joint Working Group. JCS 2017 Guideline on Management of Vasculitis Syndrome - Digest Version. Circ J. 2020;84:299\u2013359.","journal-title":"Circ J"},{"key":"2429_CR17","doi-asserted-by":"crossref","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1\u201311.","DOI":"10.1002\/art.37715"},{"key":"2429_CR18","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.21037\/jtd.2019.11.73","volume":"11","author":"H Yamakawa","year":"2019","unstructured":"Yamakawa H, Sato S, Tsumiyama E, Nishizawa T, Kawabe R, Oba T, et al. Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS\/ERS\/JRS\/ALAT criteria. J Thorac Dis. 2019;11:5247\u201357.","journal-title":"J Thorac Dis"},{"key":"2429_CR19","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","volume":"198","author":"G Raghu","year":"2018","unstructured":"Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, et al. Diagnosis of idiopathic pulmonary fibrosis. An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018;198:e44\u201368.","journal-title":"Am J Respir Crit Care Med"},{"key":"2429_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1378\/chest.12-2403","volume":"144","author":"CJ Ryerson","year":"2013","unstructured":"Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234\u201340.","journal-title":"Chest"},{"key":"2429_CR21","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.resinv.2018.12.011","volume":"57","author":"N Kuse","year":"2019","unstructured":"Kuse N, Inomata M, Awano N, Yoshimura H, Jo T, Tone M, et al. Management and utility of transbronchial lung cryobiopsy in Japan. Respir Investig. 2019;57:245\u201351.","journal-title":"Respir Investig"},{"key":"2429_CR22","doi-asserted-by":"publisher","first-page":"00008","DOI":"10.1183\/23120541.00008-2020","volume":"6","author":"M Inomata","year":"2020","unstructured":"Inomata M, Kuse N, Awano N, Tone M, Yoshimura H, Jo T, et al. Prospective multicentre study on the safety and utility of transbronchial lung cryobiopsy with endobronchial balloon. ERJ Open Res. 2020;6:00008\u20132020.","journal-title":"ERJ Open Res"},{"key":"2429_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al. An official american thoracic Society\/European respiratory society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733\u201348.","journal-title":"Am J Respir Crit Care Med"},{"key":"2429_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1378\/chest.10-0194","volume":"138","author":"A Fischer","year":"2010","unstructured":"Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest. 2010;138:251\u20136.","journal-title":"Chest"},{"key":"2429_CR25","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1378\/chest.14-3174","volume":"148","author":"N Omote","year":"2015","unstructured":"Omote N, Taniguchi H, Kondoh Y, Watanabe N, Sakamoto K, Kimura T, et al. Lung-dominant connective tissue disease: clinical, radiologic, and histologic features. Chest. 2015;148:1438\u201346.","journal-title":"Chest"},{"key":"2429_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/his.12415","volume":"65","author":"M Kambouchner","year":"2014","unstructured":"Kambouchner M, Levy P, Nicholson AG, Schubel K, Magois E, Feuillet S, et al. Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology. 2014;65:549\u201360.","journal-title":"Histopathology"},{"key":"2429_CR27","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","volume":"16","author":"H Sasano","year":"2016","unstructured":"Sasano H, Hagiwara E, Kitamura H, Enomoto Y, Matsuo N, Baba T, et al. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm Med. 2016;16:168.","journal-title":"BMC Pulm Med"},{"key":"2429_CR28","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/resp.13313","volume":"23","author":"H Yamakawa","year":"2018","unstructured":"Yamakawa H, Kitamura H, Takemura T, Ikeda S, Sekine A, Baba T, et al. Prognostic factors and disease behaviour of pathologically proven fibrotic non-specific interstitial pneumonia. Respirology. 2018;23:1032\u201340.","journal-title":"Respirology"},{"key":"2429_CR29","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1007\/s10067-021-05671-1","volume":"40","author":"WJ Wu","year":"2021","unstructured":"Wu WJ, Mo HY, Liu H. Transbronchial lung cryobiopsy for connective tissue disease-related interstitial lung disease and interstitial pneumonia with autoimmune features: a single center retrospective case series. Clin Rheumatol. 2021;40:3765\u201372.","journal-title":"Clin Rheumatol"},{"key":"2429_CR30","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/MCP.0000000000000810","volume":"27","author":"C Ravaglia","year":"2021","unstructured":"Ravaglia C, Nicholson AG. Biopsy in interstitial lung disease: specific diagnosis and the identification of the progressive fibrotic phenotype. Curr Opin Pulm Med. 2021;27:355\u201362.","journal-title":"Curr Opin Pulm Med"},{"key":"2429_CR31","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek M, Cottin V. Spectrum of fibrotic lung diseases. N Engl J Med. 2020;383:958\u201368.","journal-title":"N Engl J Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02429-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-023-02429-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-023-02429-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,18]],"date-time":"2023-04-18T06:06:12Z","timestamp":1681797972000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-023-02429-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,18]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1186\/s12890-023-02429-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2593434\/v1","asserted-by":"object"}]},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,18]]},"assertion":[{"value":"16 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the Medical Research, Saitama Red Cross Hospital (No.19-C) and the study was conducted in accordance with the Helsinki Declaration. The requirement for written informed consent was waived by the Ethics Committee of the Medical Research, Saitama Red Cross Hospital based on the retrospective nature.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"HY and SS received honoraria from Nippon Boehringer Ingelheim Co., Ltd. The other authors have no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"There are no sources of financial support to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial interest"}}],"article-number":"126"}}